Inotropic Support for Hypotension and Low Cardiac Output
For patients requiring inotropic support with low cardiac output and hypotension, dobutamine (2-20 mcg/kg/min) is the recommended first-line inotrope, with norepinephrine (not dopamine) as the preferred vasopressor if blood pressure support is needed. 1
Initial Assessment and Hemodynamic Stratification
Before initiating inotropes, rapidly assess:
- Volume status: Rule out hypovolemia with fluid challenge (200 mL saline/ringer lactate over 15-30 minutes) unless overt fluid overload is present 1
- Blood pressure: Systolic BP <90 mmHg defines cardiogenic shock when persistent >30 minutes despite adequate volume 1
- Perfusion markers: Oliguria (<0.5 mL/kg/h for ≥6 hours), altered mentation, cool extremities, lactate >2-4 mmol/L 1
Pharmacologic Strategy Based on Blood Pressure
SBP <90 mmHg with Hypoperfusion (Cardiogenic Shock)
- First-line inotrope: Dobutamine 2-5 mcg/kg/min initially, titrate up to 20 mcg/kg/min 2
- If vasopressor needed: Add norepinephrine 0.2-1.0 mcg/kg/min (NOT dopamine—norepinephrine has lower arrhythmia risk and better outcomes) 1
- Special consideration: If patient is on chronic beta-blockers, consider levosimendan (0.1 mcg/kg/min without bolus if SBP <100 mmHg) as it works distal to beta-receptors 1
SBP 90-100 mmHg with Low Output
- Start with dobutamine alone or consider levosimendan 2
- Monitor closely for hypotension requiring vasopressor addition
SBP >100 mmHg with Low Output
- Dobutamine is appropriate, but consider adding vasodilators (nitroglycerin 10-20 mcg/min) to reduce afterload once perfusion improves 2
Critical Pitfalls to Avoid
Dopamine should NOT be used as first-line vasopressor: The 2015 European consensus explicitly recommends norepinephrine over dopamine due to higher arrhythmia rates and worse outcomes in cardiogenic shock 1. While dopamine appears in older guidelines 2, the most recent high-quality evidence (2015) prioritizes norepinephrine.
Do not combine multiple inotropes: Rather than stacking inotropes, escalate to mechanical circulatory support if inadequate response occurs 1. The routine use of intra-aortic balloon pump (IABP) is NOT recommended based on the IABP-SHOCK II trial 1.
Avoid excessive doses: Dopamine >20 mcg/kg/min causes excessive vasoconstriction; dobutamine >20 mcg/kg/min increases arrhythmia risk 2
Alternative Agents
Milrinone (Phosphodiesterase-III Inhibitor)
- Dosing: 25-75 mcg/kg bolus over 10-20 min, then 0.375-0.75 mcg/kg/min 2
- Advantage: Works independently of beta-receptors, useful in beta-blocked patients
- Disadvantage: Causes vasodilation (may worsen hypotension), long half-life delays steady-state effect 3
- Consider when dobutamine is ineffective in beta-blocked patients
Levosimendan (Calcium Sensitizer)
- Dosing: 0.1 mcg/kg/min (omit 12 mcg/kg bolus if SBP <100 mmHg), can adjust 0.05-0.2 mcg/kg/min 2
- Particularly recommended: For chronic heart failure patients on beta-blockers 1
- Has both inotropic and vasodilator properties
- May not be available in all countries 1
Monitoring Requirements
- Continuous: Arterial line for blood pressure, cardiac output assessment, perfusion markers 1
- Serial assessment: Urine output, lactate clearance, mental status, extremity warmth
- Consider pulmonary artery catheter: If diagnosis unclear or inadequate response to initial therapy 4, 5
Escalation Plan
If inadequate response after 48 hours of inotropic support:
- Reassess diagnosis: Mechanical complications (ventricular septal rupture, papillary muscle rupture, tamponade) 1
- Consider mechanical support: Percutaneous ventricular assist devices, extracorporeal membrane oxygenation 1
- Transfer to tertiary center: With 24/7 cardiac catheterization and mechanical circulatory support capabilities 1
Duration and Weaning
Inotropic support beyond 48 hours requires a definitive plan: weaning strategy, transition to mechanical support, or cardiac transplantation evaluation 6. The goal is restoration of adequate perfusion (lactate clearance, urine output >0.5 mL/kg/h, warm extremities, normal mentation) rather than arbitrary blood pressure targets.